
I tried Botox to treat my migraines, here's how it went
The west of Ireland has a unique connection to Botox as a major global producer of the drug, but the substance, primarily known for banishing wrinkles, isn't solely utilised for cosmetic purposes. Its use as a medical treatment is now widely accepted.
When Kate Brayden's migraines worsened two years ago, she knew that it was time to go under the needle.
When we think of Botox, our societal obsession with youth might initially come to mind; Hollywood stars in paparazzi photos with smooth foreheads that don't move.
The neurotoxic protein (Botulinum toxin) is especially interesting in an Irish context, given that the "Botox capital of the world" is none other than Westport, Co Mayo.
In 2023, Allergan Pharmaceuticals Ireland UC's manufacturing plant in the local town increased to a record €4.43 billion, according to the released accounts.
Niche dinner party facts aside, Botox has also been used to treat various forms of pain conditions and disorders.
It has been found to block chemicals that carry pain signals to the nerves around your head and neck, making it an effective pain management tool for myofascial syndrome, headaches, migraines, arthritis and chronic back and neck pain.
The FDA approved Botox for migraine headaches in October 2010, giving Allergan clearance to begin marketing its drug to patients with a serious history of the condition. Chronic migraine is defined as having a headache on at least 15 days per month, with eight of these days featuring migraine symptoms, for at least three months.
I first started receiving Botox for migraine in 2023, after a dental surgeon recommended it for my jaw pain and throbbing temple-based migraines.
The cause of my migraine was linked to my long-term fibromyalgia, a chronic condition (presumed to be autoimmune) characterised by widespread musculoskeletal pain, fatigue, and cognitive issues.
My experience with Botox
While I have found relief from Botox, it is temporary and short-lasting. Given the cost of such a treatment, I can see how some choose to only undergo a few rounds before calling it a day. I received Botox injections both by an oral surgeon in a dental practice, as well as a pain consultant who focused on slightly different sites around my head and neck.
In total, I have tried four rounds, with varying degrees of 'success' - though we all have different definitions.
According to Dr Deborah Galvin, a Dublin-based Consultant Anaesthetist and Pain Physician:
"Success is considered as a decrease in the frequency of migraine attacks per month, pain intensity, medication use, ER visits, and migraine-related disabilities. This includes sickness leave from work, reduced productivity at work, school and home.
"If Botox does not sufficiently reduce migraines after two separate treatments, cessation should be considered."
It's important to note the cost for most patients. I had to pay between €200 and €300 per round of Botox, which is not easily accessible to many pain patients, many of whom struggle to manage working with a chronic condition.
In terms of side effects, I experienced the most common one reported by Dr Galvin: neck pain.
"Neck pain is the most common side effect reported, occurring in four per cent of patients. Other frequently reported side effects include injection site pain (two per cent), eyelid drooping (two per cent), and muscular weakness (one and a half per cent). Botox has not been studied in pregnant and breastfeeding patients, so its safety has not been established in these groups."
For anyone else cursed to keep a migraine diary, we all want to know the cause.
"CGRP is a neuropeptide which is believed to be the main culprit driving migraines in many patients," Dr Galvin elaborates. "Over the last five years, different CGRP antagonist medications have been produced, which are now the first line in the prevention of migraine.
"The most recent CGRP antagonist, Rimegepant, has been available in Ireland as a high-tech medication since February 2025. This is an oral medication."
What to try before Botox
Botox is not typically used as a first line of treatment. A full clinical history and examination are important to ensure a correct diagnosis of a migraine is given. Medications are used to prevent migraines or to help with the acute pain during a flare - triptans, CGRP antagonists, ergot derivatives, beta blockers and antidepressant medications are all options.
Dr Patrick Treacy, Medical Director at the Ailesbury Clinic, reports a multi-step approach before Botox:
"First, identify and manage triggers—stress, diet (caffeine, chocolate), sleep disturbances, or hormonal factors. I also assess for rare but critical conditions, such as a patent foramen ovale (hole in the heart).To ensure safety, I require each new patient to undergo a brain MRI to rule out serious causes of headache, such as a brain tumour."
50 to 60 per cent of Dr Galvin's migraine patients report noticeable improvement in migraine frequency after Botox, while often taking other migraine medications in parallel. Dr Treacy noted similar rates of success at the Ailesbury Clinic.
Their audits showed that over 90 percent of patients had at least a 70 percent reduction in headache days after 12 months.
Why Botox?
Why Botox works for some migraine sufferers, but not others, remains disputed.
"Botox is used to treat certain types of migraines, such as chronic, episodic, unilateral and vestibular types, with success depending on the type of migraine the person has," Dr Galvin tells me.
"Frequently, patients have not found relief from beta blockers or antidepressants. Relief lasts up to 12 weeks with a possible worsening of headaches for the initial 10-14 days.
"Effectiveness of Botox depends on the cause of migraine in the patient," Dr Galvin adds. "Certain proteins produced by neurons cause increase or decrease in the nerve signalling and the subsequent muscle, nerve and blood vessel behaviour.
"Depending on what drives migraine in a patient, Botox may be more or less effective. Also, if Botox is administered too frequently (typically more frequently than every 12 weeks), antibodies are created by the body which neutralise Botox - rendering it useless and not effective."
The reasons why Botox often improves symptoms of chronic migraine are not entirely certain, though medical practitioners like Dr Treacy have some ideas.
"The precise mechanism of Botox in migraine relief remains partially understood, but it likely blocks pain signals by inhibiting neurotransmitter release (e.g., glutamate, CGRP) in peripheral nerves, reducing central sensitisation," Dr Treacy says.
"Why it works better for some is multifaceted. Patients with clear chronic migraine, rather than mixed headache types, respond better, underscoring the need for accurate diagnosis.
"Genetic factors, differences in pain pathways, or coexisting conditions like medication-overuse headache may influence outcomes. Injection technique and practitioner experience are critical—precise targeting of trigger points, as refined in my original protocol, is essential. It's likely a combination of biological and technical factors."
Final thoughts
For anyone else who reached the end of their tether with migraines, I recommend finding a neurologist or pain doctor whom you trust wholeheartedly. Running all kinds of tests to rule out anything too scary and trying other medications first, though time-consuming and riddled with side effects, is also necessary before looking at Botox.
For me, acupuncture with cranial neck massage helped temporarily, as well as pairing lifestyle factors with managing stress. Swimming and saunas, more time to relax and no more chocolate were key for me.
Lastly, if Botox isn't entirely effective, don't lose hope. There are alternatives out there to try, like CGRP inhibitors and new medications in the pipeline. The hardest part is finding the right doctor to manage the condition with you.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Irish Times
4 hours ago
- Irish Times
Autistic man (23) ‘trapped' in psychiatric unit for five years as HSE fails to secure accommodation
A 23-year-old autistic man has been in a psychiatric unit for the last five years as the Health Service Executive (HSE) has been unable to source an appropriate care facility for him, his mother has claimed. Robert Brady, from Walkinstown, Dublin 12, has been 'trapped in a psychiatric unit for years with no end in sight', Anne Dillon said. His family is not permitted to visit him at the moment and are only allowed to receive phone calls from him inside the facility, Ms Dillon said, leaving them feeling 'crushed, devastated and broken'. Mr Brady was diagnosed with autism spectrum disorder in 2019 while under the care of the Child and Adolescent Mental Health Services at the Linn Dara inpatient facility in Ballyfermot, Dublin 10. READ MORE Ms Dillon, said he 'was abruptly removed' from this facility 'and taken on the morning of his [18th] birthday to Tallaght [University Hospital] psychiatric unit', where he has lived ever since. This is 'an environment that is not suitable for his needs', as he is non-violent and not suffering from serious mental illness, Ms Dillon said. She added that this has led to a stark deterioration in his mental and physical wellbeing. [ 'This is a very posh prison': Living in a nursing home since the age of 46 Opens in new window ] 'Nobody in his care disputes the fact that this is not a suitable environment,' she said, citing high sensory overload in a clinical setting and being 'full of people who are in the most disturbed phase of their illness'. Ms Dillon has petitioned the HSE for the past five years to secure a place in an appropriate care facility for her son. The HSE told The Irish Times that although it 'cannot comment on individual cases, we can confirm that the appropriate services are engaging directly with this service user and their family'. 'Multidisciplinary care planning for all patients is holistic and includes discharge planning', it said. In email correspondence seen by The Irish Times, Minister of State with responsibility for Mental Health Mary Butler's office wrote to Ms Dillon in April 2025 that 'the HSE indicate that [ ...] identifying an appropriate placement for him has been challenging'. Ms Butler told The Irish Times 'my priority is that anyone experiencing mental health difficulties has timely access to, and the appropriate level of care they require from our mental health services'. 'The Government is committed to ensuring that all those accessing all aspects of our health services are receiving treatment and care appropriately,' she said. [ Opinion: Children experiencing mental illness can't afford to wait for reform to happen by magic Opens in new window ] Ms Butler said she cannot comment on individual cases, but 'the HSE works in close partnership with families to identify solutions to ensure care and treatment is achieved for all patients'. Sinn Féin Senator Chris Andrews raised the case in Seanad Éireann on Tuesday, saying Mr Brady 'was completely failed by our mental health and disability services' and a 'horrendous catalogue of failures' from the State. 'His complex condition is now used to justify claims that no suitable placement exists,' he said. This is 'a situation directly caused by the State's inaction and unwillingness to provide early intervention care'. Fine Gael Seanad leader Seán Kyne, replying for the Government, said Mr Brady's was a 'specific case' that Mr Andrews should raise under a different Seanad format.


Irish Times
8 hours ago
- Irish Times
Ireland saw dramatic improvement in mortality in 20-year period, data shows
Ireland experienced a dramatic improvement in mortality across the 20-year period from 1985 to 2005, according to data from the Central Statistics Office (CSO). Heart attacks were the main cause of death in nearly two out of every 10 deaths for men and women in Ireland in 1985, and that rate reduced to just one out of every 10 deaths in 2005. The crude death rate per 100,000 of population stood at a 'very high level' at 938.2 in 1985 and had reduced by 4.5 per cent to 895.8 in 1995, the CSO figures show. The following 10-year period witnessed a further 23.7 per cent reduction in the rate, where it stood at 683.6 deaths per 100,000 of population in 2005. READ MORE From 1985 to 2005, there was a 60 per cent decrease in the mortality rate of children aged between five and nine years, while the mortality rate of those aged 15 to 19 years increased by 12.7 per cent. Over the 20-year period, crude mortality rates in infants and children up to nine years of age saw the largest decreases, while rates in those aged 15-24 years increased. Heart attacks were the number one cause of death for both males and females in 1985. Nearly one out of every four deaths for males that year was due to a heart attack, while by 2005, this had decreased to one out of every 10 deaths for males. For females, deaths due to heart attacks accounted for just under two out of every 10 deaths in 1985 and by 2005, this had fallen to one out of every 10 deaths. While deaths due to heart attacks reduced over the 20-year period, other forms of chronic ischaemic heart disease, which can include deaths due to coronary atherosclerosis and aneurysms, saw an increase in proportion of all deaths.


Agriland
9 hours ago
- Agriland
Met Éireann issues nationwide advisory for potato blight
Met Éireann has issued a Status Yellow advisory for potato blight over the coming days across the country. The national forecaster said that conditions conductive to the spread of blight will develop nationwide on Thursday and Friday (June 12-13). Met Éireann advised growers that there will be opportunities for spraying today (Wednesday, June 11). Blight Potato blight, caused by the pathogen Phytophthora infestans, poses a significant threat to potato crops in Ireland and globally. Despite recent advances in fungicides, improved varieties and better disease forecasting, Teagasc said that there is still no means of eradicating an outbreak in a crop. Therefore, disease prevention is key. Weather conditions which favour the spread of the disease occur when temperatures rise above 10°C and relative humidity rises above 95%. The typical mild, damp Irish summer can provide the ideal conditions for the spread of the disease. Teagasc has estimated that some €5 million is spent annually on fungicides in Ireland to mitigate against the disease. Met Éireann Met Éireann has said that during the coming week there will be unsettled weather across the country, with rain and showers at times. Some of the showers will be heavy and with a likelihood of thunderstorms developing, particularly in the next few days. Rainfall amounts are expected to be close to or above average in most areas, and one and a half to twice the average in parts of the east, midlands and north. Mean temperatures are expected to be close to average in the south and west, and a degree above normal values in the east and north of the country. Soil temperatures are expected to rise a little over the coming seven days. Soil moisture deficits are generally between 0mm and +45mm with the driest soils in the south. However, Met Éireann noted that most soils in the north midlands are very close to saturation. Soil moisture deficits will continue to decrease in the coming week.